Japanese Pharmaceutical Market: Sector Insights
Oct 20 2017 Read 660 Times
One of the latest market intelligence forecasts for the Japanese Pharmaceutical market from life science commercial intelligence firm Evaluate highlights both negative and positive components affecting future performance, predicting a growth rate of 3.3% (CAGR) between 2017 -2022, significantly lower than Worldwide outlook (6.5% CAGR).
According to the industry analyst the enforcement of a much more stringent pricing revision policy in Japan, both for new products as well as off-patent brands, is behind the decline of the products currently on the market which are forecast to drop about 2% annually in sales through 2022.
The prices of Gilead’s hepatitis C virus (HCV) blockbusters Sovaldi and Harvoni have been subject to significant price scrutiny and most recently the Japanese government has forced a price reduction of 50% on Opdivo, BMS’ novel PD-1/PD-L1 agent.
However, the sales decline of marketed products is counterbalanced by the optimism surrounding new therapies coming to market expected to account for 34% of sales in 2022, among the top ranking are Dupixent (Sanofi), Ibrance (Pfizer), Entresto (Novartis), Aducanumab (Biogen), and Emicizumab (Chugai).
For more information on consensus drug forecasts for the Japanese Pharma and Biotech sector visit www.evaluate.com
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Using Electron Paramagnetic Resonance (EPR) to Track Free Radicals in the Environment - Determining Hazardous Substances at Arm’s Length - Column Technology for...
View all digital editions
Sep 25 2018 Kielce, Poland
Sep 27 2018 Manchester, UK
Oct 02 2018 Utrecht, Holland
Oct 09 2018 Gothenburg, Sweden
Oct 10 2018 Yangon, Myanmar